Zentalis Pharmaceuticals Inc. (ZNTL)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 0 |
| Ownership rank: | -- |
| % of all portfolios: | 0% |
| |
| Total insider Buys/Sells last 6 months: |
| Transactions | Total |
| Buys |
4 |
$223,413 |
| Sells |
5 |
$70,570 |
|
Portfolio Manager |
% of portfolio |
Recent activity |
Shares |
Value |
Open Market Insider Buys
| Date Filed |
Reporting Name |
Relationship |
Trans. Date |
Shares |
Price $ |
Total Value $ |
| 12 Feb 2025 |
BRUNS INGMAR |
Chief Medical Officer |
06 Feb 2025 |
20,000 |
2.28 |
45,656 |
| 04 Feb 2025 |
SKVARKA JAN |
Director |
31 Jan 2025 |
60,000 |
1.72 |
103,446 |
| 04 Feb 2025 |
WALKER LUKE NATHANIEL |
Director |
31 Jan 2025 |
14,200 |
1.76 |
24,966 |
| 04 Feb 2025 |
EASTLAND JULIA MARIE |
CEO & President |
31 Jan 2025 |
28,500 |
1.73 |
49,345 |
| 13 Nov 2023 |
JOHNSON DAVID MICHAEL |
Director |
10 Nov 2023 |
17,000 |
9.88 |
167,943 |
| 13 Nov 2023 |
BLACKWELL KIMBERLY |
Chief Executive Officer |
13 Nov 2023 |
5,000 |
10.29 |
51,448 |
| 20 Jun 2023 |
MATRIX CAPITAL MANAGEMENT COMPANY, LP |
10% |
20 Jun 2023 |
4,760,000 |
22.66 |
107,861,600 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.
P = Preferred Stock